{"id":"https://openalex.org/W7224842003","doi":"https://doi.org/10.1021/acs.jmedchem.6c02625","title":"Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant","display_name":"Discovery of INCB161734: A Selective Inhibitor of the KRAS G12D Mutant","publication_year":2026,"publication_date":"2026-10-30","ids":{"openalex":"https://openalex.org/W7224842003","doi":"https://doi.org/10.1021/acs.jmedchem.6c02625","pmid":"https://pubmed.ncbi.nlm.nih.gov/43018629"},"language":"en","primary_location":{"id":"doi:10.1021/acs.jmedchem.6c02625","doi":"https://doi.org/10.1021/acs.jmedchem.6c02625","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.6c02625","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088146420","display_name":"Alexander Sokolsky","orcid":"https://orcid.org/0000-0001-9974-8948","observed_orcids":["https://orcid.org/0000-0001-9974-8948"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Alexander Sokolsky","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":"https://orcid.org/0000-0001-9974-8948","affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160194319","display_name":"Haolin Yin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haolin Yin","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044882995","display_name":"Qinda Ye","orcid":"https://orcid.org/0000-0002-7864-1751","observed_orcids":["https://orcid.org/0000-0002-7864-1751"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qinda Ye","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115808531","display_name":"Peter Carlsen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Carlsen","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160202066","display_name":"Chunyin Law","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chunyin Law","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5115808533","display_name":"Matthew S. McCammant","orcid":"https://orcid.org/0009-0006-9961-2796","observed_orcids":["https://orcid.org/0009-0006-9961-2796"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew S. McCammant","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":"https://orcid.org/0009-0006-9961-2796","affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066762752","display_name":"Rocco L. Policarpo","orcid":"https://orcid.org/0000-0001-9819-2394","observed_orcids":["https://orcid.org/0000-0001-9819-2394"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rocco Policarpo","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023418454","display_name":"Padmaja K Polam","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Padmaja Polam","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137117975","display_name":"Le Zhao","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Le Zhao","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160203148","display_name":"Fenglei Zhang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Fenglei Zhang","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160228072","display_name":"Gencheng Li","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gencheng Li","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160191342","display_name":"Bin Hu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bin Hu","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113207046","display_name":"Wenyu Zhu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wenyu Zhu","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160161334","display_name":"Gia Hoang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gia Hoang","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043133161","display_name":"Robert Susick","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert Susick","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068148700","display_name":"Zhenwu Li","orcid":"https://orcid.org/0000-0003-0962-5931","observed_orcids":["https://orcid.org/0000-0003-0962-5931"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Zhenwu Li","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011119662","display_name":"Pei Gan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Pei Gan","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004348569","display_name":"Artem Shvartsbart","orcid":"https://orcid.org/0000-0002-1438-3095","observed_orcids":["https://orcid.org/0000-0002-1438-3095"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Artem Shvartsbart","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076949187","display_name":"Jeremy J. Roach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy J. Roach","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5160197520","display_name":"Chao Qi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chao Qi","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075559641","display_name":"Sean Bowen","orcid":"https://orcid.org/0000-0003-1047-4325","observed_orcids":["https://orcid.org/0000-0003-1047-4325"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sean Bowen","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5152457783","display_name":"Chengtsung Lai","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chengtsung Lai","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011775533","display_name":"Abdellah Allali\u2010Hassani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abdellah Allali-Hassani","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022122887","display_name":"Keith Kennedy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Keith Kennedy","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025853795","display_name":"Leslie B. Epling","orcid":"https://orcid.org/0000-0003-4897-1300","observed_orcids":["https://orcid.org/0000-0003-4897-1300"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leslie B. Epling","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5094224241","display_name":"Alexandra Gallion","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alexandra Gallion","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072989379","display_name":"Kerri Kurzeja-Lipinski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kerri Kurzeja-Lipinski","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066571466","display_name":"Karen Gallagher","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Karen Gallagher","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058888569","display_name":"Valerie Dostalik Roman","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Valerie Roman","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036794959","display_name":"Matthew R. Farren","orcid":"https://orcid.org/0000-0001-5510-8869","observed_orcids":["https://orcid.org/0000-0001-5510-8869"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Matthew R. Farren","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5158841539","display_name":"Weixi Kong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Weixi Kong","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5126157936","display_name":"Guofeng Zhang","orcid":"https://orcid.org/0000-0001-9675-2044","observed_orcids":["https://orcid.org/0000-0001-9675-2044"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Guofeng Zhang","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048234112","display_name":"Jason Boer","orcid":"https://orcid.org/0009-0008-5628-0028","observed_orcids":["https://orcid.org/0009-0008-5628-0028"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Boer","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072187299","display_name":"Marc C. Deller","orcid":"https://orcid.org/0000-0001-8070-6502","observed_orcids":["https://orcid.org/0000-0001-8070-6502"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc C. Deller","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5137085059","display_name":"Hui Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hui Wang","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109122502","display_name":"Maryanne B. Covington","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maryanne Covington","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077094654","display_name":"Jennifer J. Harris","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer J. Harris","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062439530","display_name":"S. Kim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunkyu Kim","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035647861","display_name":"Dashyant Dhanak","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dashyant Dhanak","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084386900","display_name":"Wenqing Yao","orcid":"https://orcid.org/0009-0004-0369-4623","observed_orcids":["https://orcid.org/0009-0004-0369-4623"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Wenqing Yao","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5084225119","display_name":"Xiaozhao Wang","orcid":"https://orcid.org/0009-0002-0257-4393","observed_orcids":["https://orcid.org/0009-0002-0257-4393"]},"institutions":[{"id":"https://openalex.org/I924451375","display_name":"Incyte (United States)","ror":"https://ror.org/00cvzzg84","country_code":"US","type":"company","lineage":["https://openalex.org/I924451375"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaozhao Wang","raw_affiliation_strings":["Incyte Corporation , , 1801 Augustine Cut-off , , ,"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Incyte Corporation , , 1801 Augustine Cut-off , , ,","institution_ids":["https://openalex.org/I924451375"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5088146420"],"corresponding_institution_ids":["https://openalex.org/I924451375"],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"69","issue":"21","first_page":"25112","last_page":"25127"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.7768999934196472,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.7768999934196472,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.03929999843239784,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.03620000183582306,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/kras-g12d-inhibitors","display_name":"KRAS G12D inhibitors","score":0.8870000243186951},{"id":"https://openalex.org/keywords/kras-g12d-mutation","display_name":"KRAS G12D mutation","score":0.8560000061988831},{"id":"https://openalex.org/keywords/small-molecule-kinase-inhibitors","display_name":"small-molecule kinase inhibitors","score":0.7070000171661377},{"id":"https://openalex.org/keywords/drug-discovery","display_name":"drug discovery","score":0.621999979019165},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.6650000214576721},{"id":"https://openalex.org/keywords/metabolic-clearance","display_name":"metabolic clearance","score":0.5600000023841858},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.777999997138977},{"id":"https://openalex.org/keywords/drug-likeness","display_name":"drug-likeness","score":0.6190000176429749},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.8059999942779541},{"id":"https://openalex.org/keywords/xenograft-tumor-model","display_name":"xenograft tumor model","score":0.9229999780654907}],"concepts":[{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.8205000162124634},{"id":"https://openalex.org/C2781187634","wikidata":"https://www.wikidata.org/wiki/Q20969980","display_name":"KRAS","level":4,"score":0.8172000050544739},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.638700008392334},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.5307000279426575},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.519599974155426},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.487199991941452},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.47859999537467957},{"id":"https://openalex.org/C181389837","wikidata":"https://www.wikidata.org/wiki/Q461809","display_name":"Bioavailability","level":2,"score":0.4620000123977661},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.4357999861240387},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3993000090122223},{"id":"https://openalex.org/C2991874392","wikidata":"https://www.wikidata.org/wiki/Q1124842","display_name":"Metabolic stability","level":3,"score":0.3939000070095062},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.35899999737739563},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3549000024795532},{"id":"https://openalex.org/C6555983","wikidata":"https://www.wikidata.org/wiki/Q7181398","display_name":"Phenotypic screening","level":4,"score":0.32919999957084656},{"id":"https://openalex.org/C74187038","wikidata":"https://www.wikidata.org/wiki/Q1418791","display_name":"Drug discovery","level":2,"score":0.3188000023365021},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.31139999628067017},{"id":"https://openalex.org/C193042331","wikidata":"https://www.wikidata.org/wiki/Q1772003","display_name":"Structure\u2013activity relationship","level":3,"score":0.3102000057697296},{"id":"https://openalex.org/C2777752497","wikidata":"https://www.wikidata.org/wiki/Q286779","display_name":"IC50","level":3,"score":0.2912999987602234},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.2687999904155731},{"id":"https://openalex.org/C3020616263","wikidata":"https://www.wikidata.org/wiki/Q1216998","display_name":"Tumor cells","level":2,"score":0.2680000066757202}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009154","descriptor_name":"Mutation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010879","descriptor_name":"Piperazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016283","descriptor_name":"Proto-Oncogene Proteins p21(ras)","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045744","descriptor_name":"Cell Line, Tumor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1021/acs.jmedchem.6c02625","doi":"https://doi.org/10.1021/acs.jmedchem.6c02625","is_oa":false,"landing_page_url":"https://doi.org/10.1021/acs.jmedchem.6c02625","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:43018629","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/43018629","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.8371999859809875}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320317544","display_name":"Incyte","ror":"https://ror.org/00cvzzg84"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":44,"referenced_works":["https://openalex.org/W1970527559","https://openalex.org/W1971102429","https://openalex.org/W2036260921","https://openalex.org/W2044485322","https://openalex.org/W2059015914","https://openalex.org/W2074274985","https://openalex.org/W2083003895","https://openalex.org/W2122839730","https://openalex.org/W2128339707","https://openalex.org/W2182290275","https://openalex.org/W2184779060","https://openalex.org/W2335442430","https://openalex.org/W2597182072","https://openalex.org/W2732767128","https://openalex.org/W2769098871","https://openalex.org/W2889741479","https://openalex.org/W2963086398","https://openalex.org/W2982321167","https://openalex.org/W3172081492","https://openalex.org/W4200173198","https://openalex.org/W4213177438","https://openalex.org/W4223603119","https://openalex.org/W4281650778","https://openalex.org/W4307425458","https://openalex.org/W4322719806","https://openalex.org/W4362536215","https://openalex.org/W4362541388","https://openalex.org/W4365511916","https://openalex.org/W4365512061","https://openalex.org/W4384662540","https://openalex.org/W4385931420","https://openalex.org/W4389227452","https://openalex.org/W4389239767","https://openalex.org/W4393072782","https://openalex.org/W4393075420","https://openalex.org/W4393087218","https://openalex.org/W4393087374","https://openalex.org/W4394580100","https://openalex.org/W4394595642","https://openalex.org/W4400084849","https://openalex.org/W4406166696","https://openalex.org/W4407898113","https://openalex.org/W4410596350","https://openalex.org/W4410816242"],"related_works":["https://openalex.org/W4393093742","https://openalex.org/W4406166696","https://openalex.org/W4415939666","https://openalex.org/W4318822823","https://openalex.org/W7133241897","https://openalex.org/W4389227452","https://openalex.org/W7116908857","https://openalex.org/W4415941073","https://openalex.org/W4393086401","https://openalex.org/W4400034735"],"abstract_inverted_index":{"The":[0],"discovery":[1],"of":[2,32,40],"the":[3,26,41,53],"clinical":[4,100],"KRAS":[5,105],"G12D":[6,106],"inhibitor":[7],"INCB161734":[8,72,96],"is":[9,97],"described.":[10],"Starting":[11],"from":[12],"a":[13,21,76],"previously":[14],"disclosed":[15],"orally":[16],"bioavailable":[17],"tool":[18],"compound":[19,78],"1,":[20],"concerted":[22],"effort":[23],"to":[24,46,63],"improve":[25,64],"predicted":[27],"human":[28],"dose":[29],"via":[30],"modulation":[31],"potency":[33],"and":[34,56,66,90],"pharmacokinetics":[35],"was":[36,44,73],"undertaken.":[37],"Careful":[38],"consideration":[39],"metabolic":[42],"profile":[43],"key":[45],"designing":[47],"low":[48],"clearance":[49],"compounds.":[50],"In":[51],"addition,":[52],"molecular":[54],"size":[55],"fraction":[57],"sp3":[58],"character":[59],"were":[60],"carefully":[61],"controlled":[62],"permeability":[65],"crystalline":[67],"solubility.":[68],"From":[69],"this":[70],"effort,":[71],"identified":[74],"as":[75],"balanced":[77],"with":[79,104],"excellent":[80,91],"oral":[81],"exposure,":[82],"potent":[83],"antiproliferative":[84],"activity":[85],"in":[86,102],"xenograft":[87],"tumor":[88],"models,":[89],"selectivity":[92],"against":[93],"wild-type":[94],"K/H/NRAS.":[95],"currently":[98],"undergoing":[99],"trials":[101],"patients":[103],"mutations.":[107]},"counts_by_year":[],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2026-10-31T00:00:00"}